<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="4534"><DrugName>terflavoxate</DrugName><DrugNamesKey><Name id="42756645">terflavoxate</Name></DrugNamesKey><DrugSynonyms><Name><Value>Rec-15-2053</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>terflavoxate</Value><Types><Type>INN</Type></Types></Name><Name><Value>ND-907</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>86433-39-8</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>86433-40-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="24154">Recordati SpA</CompanyOriginator><CompaniesSecondary><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Company id="18552">Nippon Shinyaku Co Ltd</Company><Company id="24154">Recordati SpA</Company></CompaniesSecondary><CrossReferences><SourceEntity id="4534" type="Drug"><TargetEntity id="148958" type="siDrug">Terflavoxate hydrochloride</TargetEntity></SourceEntity><SourceEntity id="18552" type="Company"><TargetEntity id="4295877838" type="organizationId">Nippon Shinyaku Co Ltd</TargetEntity></SourceEntity><SourceEntity id="24154" type="Company"><TargetEntity id="4295875399" type="organizationId">Recordati Industria Chimica e Farmaceutica SpA</TargetEntity></SourceEntity><SourceEntity id="187" type="ciIndication"><TargetEntity id="10046543" type="MEDDRA"></TargetEntity><TargetEntity id="D014549" type="MeSH"></TargetEntity><TargetEntity id="-1859456438" type="omicsDisease"></TargetEntity><TargetEntity id="355" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="454" type="ciIndication"><TargetEntity id="10036018" type="MEDDRA"></TargetEntity><TargetEntity id="4698" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="259" type="Action"><TargetEntity id="3" type="Mechanism">Muscarinic Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="C2">Phase 2 Clinical</PhaseTerminated><IndicationsSecondary><Indication id="187">Urinary incontinence</Indication><Indication id="454">Pollakiuria</Indication></IndicationsSecondary><ActionsPrimary><Action id="259">Muscarinic receptor antagonist</Action></ActionsPrimary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>G4B4</Code><Name>Urinary incontinence products</Name></Ephmra></EphmraCodes><LastModificationDate>2017-11-29T17:35:03.000Z</LastModificationDate><ChangeDateLast>2008-04-30T15:41:08.000Z</ChangeDateLast><AddedDate>1996-02-16T00:00:00.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="4534" linkType="Drug"&gt;Terflavoxate&lt;/ulink&gt; is an acetylcholine (ACh) muscarinic antagonist which was under development by &lt;ulink linkID="24154" linkType="Company"&gt;Recordati&lt;/ulink&gt; as an antispasmodic. It reached phase II clinical trials for the potential treatment of urinary tract diseases such as incontinence and pollakiuria [&lt;ulink linkID="11354" linkType="reference"&gt;11354&lt;/ulink&gt;]. However, in May 1996, the company announced that it had discontinued further development of the compound, because it was found to affect liver enzymes, and hence interact with other drugs [&lt;ulink linkID="216449" linkType="reference"&gt;216449&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The compound had the effect of increasing bladder capacity without causing residual urine. It could be administered once daily due to its long duration of action [&lt;ulink linkID="191067" linkType="reference"&gt;191067&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;ulink linkID="15606" linkType="Company"&gt;Dainippon&lt;/ulink&gt; and &lt;ulink linkID="18552" linkType="Company"&gt;Nippon Shinyaku&lt;/ulink&gt; had the marketing rights for &lt;ulink linkID="4534" linkType="Drug"&gt;terflavoxate&lt;/ulink&gt; for the treatment of urinary incontinence in Japan as well as some other Far East countries [&lt;ulink linkID="181223" linkType="reference"&gt;181223&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="454">Pollakiuria</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="454">Pollakiuria</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24154">Recordati SpA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="454">Pollakiuria</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24154">Recordati SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="454">Pollakiuria</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="187">Urinary incontinence</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24154">Recordati SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="187">Urinary incontinence</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="24154">Recordati SpA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="187">Urinary incontinence</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="187">Urinary incontinence</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="187">Urinary incontinence</Indication><StatusDate>1996-05-31T00:00:00.000Z</StatusDate><Source id="216449" type="SERIAL"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><Source id="181223" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><Source id="181223" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15606">Dainippon Pharmaceutical Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="454">Pollakiuria</Indication><Source id="187426" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><Source id="181223" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><Source id="181223" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="18552">Nippon Shinyaku Co Ltd</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="454">Pollakiuria</Indication><Source id="187426" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24154">Recordati SpA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="454">Pollakiuria</Indication><Source id="216451" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24154">Recordati SpA</Company><Country id="XW">Western Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><Source id="216451" type="SERIAL"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24154">Recordati SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="187">Urinary incontinence</Indication><Source id="181223" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="24154">Recordati SpA</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="454">Pollakiuria</Indication></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-01362"><Name>Muscarinic receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1167241">Finanziaria Industriale Mobiliare ed Immobiliare SPA</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="18552">Nippon Shinyaku Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20268">Sumitomo Chemical Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="5">Drug - Commercialization License</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>Cc1c(=O)c2cccc(c2oc1c3ccccc3)C(=O)OC(C)(C)CN4CCCCC4</Smiles><Smiles>Cc1c(=O)c2cccc(c2oc1c3ccccc3)C(=O)OC(C)(C)CN4CCCCC4.Cl</Smiles></StructureSmiles><Deals><Deal id="112461" title="Nippon Shinyaku to market Recordati's terflavoxate in Japan and the Far East "/><Deal id="112462" title="Dainippon Pharmaceutical to market Recordati's terflavoxate in Japan and the Far East "/></Deals><hasSWOTs>N</hasSWOTs></drugRecordOutput>